Pharmacokinetics of antifungals: Implications for drug selection

Infections in Medicine

Volumn 23, Issue 7, 2006, Pages 328-333

  Smith, Jeanina ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antifungals; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA MENINGITIS; DRUG BRAIN LEVEL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG PENETRATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PHARMACODYNAMICS; VITREOUS BODY;

EID: 33748544827     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Andes D, Cralg WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 2002;19:261-268.
2. Andes D. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr Opin Investig Drug. 2003;4:991-998.
3. Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am. 2003;17: 599-613.
4. Muller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441-1453.
5. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310-350.
6. Odds FC. Candida infections: an overview. Crit Rev Microbiol. 1987;15:1-5.
7. Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986;29:579-583.
8. Woods JP, Heinecke EL, Luecke JW, et al. Pathogenesis of Histoplasma capsulatum. Semin Respir Infect. 2001;16:91-101.
9. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105-109.
10. Komiya I, Umemura K, Fujita M, et al. Mechanism of renal distribution of aminoglycoside antibiotics. J Pharmacobiodyn. 1980;3:299-308.
11. de la Pena A, Liu P, Derendorf H. Microdialysis in peripheral tissues. Adv Drug Deliv Rev. 2000; 45:189-216.
12. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(suppl 3): S318-S326.
13. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988;32:1-8.
14. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am. 1999;13:595-618.
15. Stamey TA, Fair WR, Timothy MM, et al. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974;291:1159-1163.
16. Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46:828-833.
17. Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent in human plasma and urine. Drug Metab Dispos. 2000;28:1274-1278.
18. Polak A, Eschenhof E, Fernex M, Scholer HJ. Metabolic studies with 5-fluorocytosiner6-14C in mouse, rat, rabbit, dog and man. Chemotherapy. 1976;22:137-153.
19. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of ampho tericin B in humans. J Infect Dis. 1985;152:1037-1043.
20. Collette N, van der Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989;33:362-368.
21. Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother. 2001;45:1184-1191.
22. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46: 2546-2553.
23. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274-282.
24. Mian UK, Mayers M, Garg Y, et al. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J Ocul Pharmacol Ther. 1998;14:459-471.
25. Sorensen KN, Sobel RA, demons KV, et al. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother. 2000;44:1512-1517.
26. Utz JP, Garriques IL, Sande MA, et al. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis. 1975; 132:368-373.
27. Green WR, Bennett JE, Goos RD. Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical cephalosporium endophthalmitis. Arch Ophthalmol. 1965;73:769-775.
28. Louie A, Liu W, Miller DA, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother. 1999;43:2831-2840.
29. Hariprasad SM, Mieler WF, HoIz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42-47.
30. Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother. 2002;46: 3719-3723.
31. Fisher JF, Taylor AT, Clark J, et al. Penetration of amphotericin B into the human eye. J Infect Dis. 1983;147:164.
32. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987;31:6-10.
33. O'Day DM, Foulds G, Williams TE, et al. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990;108:1006-1008.
34. Walsh A, Haft DA, Miller MH, et al. Ocular penetration of 5-fluorocytosine. Invest Ophthalmol Vis Sci. 1978;17:691-694.
35. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
36. Klotz SA, Perm CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000;13:662-685.
37. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27: 603-618.
38. Matot I, Pizov R, Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med. 2000;28:2528-2532.
39. Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med. 1997;3:170-174.
40. Yamazaki K, Ogura S, Ishizaka A, et al. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med. 2003;168:1304-1307.
41. Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother. 2004;48:3823-3827.
42. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and its Lipid Formulations. ICAAC; 2003.